Calder Biosciences announces clinical supply agreement with Biodextris to evaluate its lead RSV vaccine candidate as part of a Phase 1 clinical trial

BOSTON, June 6, 2023 /PRNewswire/ - Calder Biosciences Inc., a molecular engineering and clinical manufacturing-stage biotechnology company pioneering its 3D-Vaxlockä platform technology to engineer and develop novel protein subunit vaccines, today announced a clinical supply agreement with Biodextris Inc.

NewsGuest UserJune 12, 2023BIOOQuébecBiosciences